IL116769A - 2,9-Disubstituted purin-6-one compounds their preparation and pharmaceutical compositions containing them - Google Patents

2,9-Disubstituted purin-6-one compounds their preparation and pharmaceutical compositions containing them

Info

Publication number
IL116769A
IL116769A IL11676996A IL11676996A IL116769A IL 116769 A IL116769 A IL 116769A IL 11676996 A IL11676996 A IL 11676996A IL 11676996 A IL11676996 A IL 11676996A IL 116769 A IL116769 A IL 116769A
Authority
IL
Israel
Prior art keywords
carbon atoms
chain
straight
branched alkyl
phenyl
Prior art date
Application number
IL11676996A
Other languages
English (en)
Other versions
IL116769A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL116769A0 publication Critical patent/IL116769A0/xx
Publication of IL116769A publication Critical patent/IL116769A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11676996A 1995-01-19 1996-01-16 2,9-Disubstituted purin-6-one compounds their preparation and pharmaceutical compositions containing them IL116769A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (2)

Publication Number Publication Date
IL116769A0 IL116769A0 (en) 1996-05-14
IL116769A true IL116769A (en) 1998-12-06

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11676996A IL116769A (en) 1995-01-19 1996-01-16 2,9-Disubstituted purin-6-one compounds their preparation and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (1) US5861404A (cs)
EP (1) EP0722944A1 (cs)
JP (1) JPH08231545A (cs)
KR (1) KR960029334A (cs)
CN (1) CN1135485A (cs)
AR (1) AR002953A1 (cs)
AU (1) AU4097996A (cs)
BG (1) BG61728B1 (cs)
BR (1) BR9600147A (cs)
CA (1) CA2167353A1 (cs)
CO (1) CO4700523A1 (cs)
CZ (1) CZ16696A3 (cs)
DE (1) DE19501482A1 (cs)
EE (1) EE9600018A (cs)
FI (1) FI960225L (cs)
HR (1) HRP960007A2 (cs)
HU (1) HUP9600106A3 (cs)
IL (1) IL116769A (cs)
MA (1) MA23778A1 (cs)
NO (1) NO960223L (cs)
NZ (1) NZ280830A (cs)
PE (1) PE64996A1 (cs)
PL (1) PL312354A1 (cs)
SG (1) SG50401A1 (cs)
SK (1) SK8096A3 (cs)
SV (1) SV1996000006A (cs)
TN (2) TNSN96006A1 (cs)
TR (1) TR199600028A2 (cs)
TW (1) TW314519B (cs)
YU (1) YU1396A (cs)
ZA (1) ZA96398B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
CN1130363C (zh) * 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
AU1688599A (en) * 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
WO2000068231A1 (en) * 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
CN1264574C (zh) * 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
MA55556A (fr) 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BG100292A (bg) 1996-07-31
SG50401A1 (en) 1998-07-20
HUP9600106A3 (en) 1998-04-28
SK8096A3 (en) 1996-08-07
DE19501482A1 (de) 1996-07-25
AR002953A1 (es) 1998-05-27
TNSN96006A1 (fr) 2005-03-15
SV1996000006A (es) 1996-10-29
BR9600147A (pt) 1998-01-06
CA2167353A1 (en) 1996-07-20
TNSN96007A1 (fr) 2005-03-15
PL312354A1 (en) 1996-07-22
TR199600028A2 (tr) 1996-08-21
HU9600106D0 (en) 1996-03-28
NO960223D0 (no) 1996-01-18
PE64996A1 (es) 1997-03-09
CO4700523A1 (es) 1998-12-29
FI960225A0 (fi) 1996-01-17
FI960225A7 (fi) 1996-07-20
IL116769A0 (en) 1996-05-14
AU4097996A (en) 1996-07-25
TW314519B (cs) 1997-09-01
MA23778A1 (fr) 1996-10-01
EE9600018A (et) 1996-08-15
ZA96398B (en) 1996-08-28
CN1135485A (zh) 1996-11-13
EP0722944A1 (de) 1996-07-24
CZ16696A3 (en) 1996-08-14
YU1396A (sh) 1999-03-04
HRP960007A2 (en) 1998-02-28
US5861404A (en) 1999-01-19
BG61728B1 (bg) 1998-04-30
NO960223L (no) 1996-07-22
HUP9600106A2 (en) 1997-05-28
NZ280830A (en) 1998-04-27
FI960225L (fi) 1996-07-20
KR960029334A (ko) 1996-08-17
JPH08231545A (ja) 1996-09-10

Similar Documents

Publication Publication Date Title
AU704102B2 (en) 2,8-disubstituted quinazolinones
IL116769A (en) 2,9-Disubstituted purin-6-one compounds their preparation and pharmaceutical compositions containing them
US6174884B1 (en) 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
AU720305B2 (en) Purin-6-one derivatives
US6458796B1 (en) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
KR101491938B1 (ko) Ｉｐ 수용체 효능제 헤테로시클릭 화합물
EP1309594B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
WO1997003985A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
JP2672290B2 (ja) 新規なピロロカルバゾール類
US5866571A (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones
HU208824B (en) Process for the production of selestive adenozine antagonistic xantine derivatives and medical preparations containing them as active agents
US6949652B2 (en) Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
WO2008031788A1 (en) Aminoazepine derivatives as highly efficient inhibitors of the inducible nitric oxide synthase

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees